PDCD1 and hemophagocytic syndrome: analyzed 16 patients with CAEBV who received PD-1 inhibitors (two pembrolizumab, nine sintilimab, and five nivolumab) but did not have HLH, and evaluated the efficacy and safety of PD-1 inhibitors (14).